Formulating Paclitaxel in Nanoparticles Alters Its Disposition
- 8 June 2005
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pharmaceutical Research
- Vol. 22 (6), 867-874
- https://doi.org/10.1007/s11095-005-4581-4
Abstract
Paclitaxel is active and widely used to treat multiple types of solid tumors. The commercially available paclitaxel formulation uses Cremophor/ethanol (C/E) as the solubilizers. Other formulations including nanoparticles have been introduced. This study evaluated the effects of nanoparticle formulation of paclitaxel on its tissue distribution.Keywords
This publication has 27 references indexed in Scilit:
- Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer TherapyClinical Cancer Research, 2004
- Metabolism of paclitaxel in miceAnti-Cancer Drugs, 2003
- Drug Delivery and Transport to Solid TumorsPharmaceutical Research, 2003
- Cremophor reduces paclitaxel penetration into bladder wall during intravesical treatmentCancer Chemotherapy and Pharmacology, 1999
- Tissue distribution, metabolism and excretion of paclitaxel in miceAnti-Cancer Drugs, 1996
- Isocratic high-performance liquid chromatographic assay of taxol in biological fluids and tissues using automated column switchingJournal of Chromatography B: Biomedical Sciences and Applications, 1995
- Body distribution of intravenously administered gelatin with different molecular weightsJournal of Controlled Release, 1994
- Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations.Proceedings of the National Academy of Sciences, 1993
- In Vivo Uptake of Polyisobutyl Cyanoacrylate Nanoparticles by Rat Liver Kupffer, Endothelial, andParenchymal CellsJournal of Pharmaceutical Sciences, 1984
- DISTRIBUTION OF BLOOD IN THE FUNCTIONAL KIDNEYThe Journal of Experimental Medicine, 1956